What does tesamorelin cost in each channel?
Prices in US dollars at the verification date. Ranges are published list or program prices where a primary source exists; notes say when a figure is a typical market range instead.
| Channel | Price (USD) | Notes |
|---|---|---|
| With insurance | Not published | Covered for the approved indication (excess abdominal fat in adults with HIV and lipodystrophy), usually with prior authorization through a specialty pharmacy. The manufacturer runs a co-pay assistance program for eligible commercially insured patients; no dated out of pocket price is published, and cost depends on the plan and program eligibility. [4] [8] |
| Branded, from a pharmacy | $10,709per month | Egrifta WR retail cash price for one kit, which the FDA label describes as four 11.6 mg vials, each providing 7 daily doses, so one kit is a 28 day supply. A published cash price listing checked 2026-09-22 showed $10,708.84 per kit. A second price comparison site listed a much higher cash price for the same kit on the same day, so cash quotes vary widely by pharmacy. Egrifta WR, approved March 2025, replaced Egrifta SV. [2] [3] [5] [6] |
| Compounded pharmacy | Not published | No lawful compounded price. On March 23, 2020 FDA deemed the Egrifta application (022505) to be a biologics license, and FDA states that biological products are not eligible for the 503A or 503B compounding exemptions. Compounded tesamorelin advertised by telehealth programs and clinics is not a lawful product, so its prices are not listed here. [7] [9] |
What is the list price of tesamorelin?
Egrifta WR is a specialty drug and the manufacturer does not publish a list price. A retail cash listing checked 2026-09-22 put one 28 day kit at $10,708.84, reflecting its orphan-scale HIV indication.
Does insurance cover tesamorelin?
Plans cover Egrifta WR only for HIV associated lipodystrophy, usually with prior authorization. Off-label use for general fat loss is not covered, so it is usually paid at the cash price.
What changes the price?
- Approved HIV indication with coverage versus off-label cash use
- Manufacturer co-pay program eligibility
- Cash price differences between pharmacies
- Loss of any lawful compounded supply after the 2020 biologic transition
Frequently asked questions
How much does tesamorelin cost without insurance?
About $10,709 per month at the verification date, depending on the channel: branded, from a pharmacy. See the table above for what each figure includes. [2] [3] [5] [6]
Does insurance cover tesamorelin?
Plans cover Egrifta WR only for HIV associated lipodystrophy, usually with prior authorization. Off-label use for general fat loss is not covered, so it is usually paid at the cash price. [4] [8]
What is the list price of tesamorelin?
Egrifta WR is a specialty drug and the manufacturer does not publish a list price. A retail cash listing checked 2026-09-22 put one 28 day kit at $10,708.84, reflecting its orphan-scale HIV indication. [2] [3] [5] [6]
Related pages
- Tesamorelin: evidence, legality, and access
- Sermorelin vs tesamorelin (Sermorelin cost)
- Tesamorelin vs CJC-1295 (CJC-1295 cost)
- Tesamorelin vs ipamorelin (Ipamorelin cost)
- Tesamorelin vs MK-677 (ibutamoren)
- Tesamorelin vs retatrutide (Retatrutide cost)
- Growth hormone deficiency and GH secretagogue use: peptide evidence
- Fatty liver disease (MASLD and MASH): peptide evidence
- Fat loss and body composition: peptide evidence
- HIV associated lipodystrophy: peptide evidence
- Where it is legal to get: peptide law by state
- Full cost index
From the blog
- Tesamorelin vs HGH: how they differ and which is approved
Tesamorelin (Egrifta) signals the pituitary to release growth hormone and is approved for HIV-associated belly fat; HGH (somatropin) is the hormone itself, approved for other conditions.
- Does tesamorelin build muscle? What the trials show
Tesamorelin raised lean body mass about 1.2 kg in HIV trials and slightly increased trunk muscle area, but no trial tested strength or muscle growth, and it is prohibited in sport.
- Tesamorelin before and after: what the trials measured
Tesamorelin results from the 26 and 52 week trials: about 15 to 18% less visceral fat, little change in weight, and fat that came back after stopping. Why photos are not trial data.
- Tesamorelin prescription: who qualifies and how to get one
How to get tesamorelin legally: who qualifies for Egrifta WR on label, how off-label prescribing works, why compounded tesamorelin is not lawful, what a visit should check, and cost.
- Tesamorelin vs sermorelin vs ipamorelin: evidence and legality
Tesamorelin, sermorelin, and ipamorelin compared in one table: mechanism, FDA approval, compounding status, human evidence, and WADA status, with links to each pairwise comparison.
- How to get peptides prescribed legally in 2026
Which peptides a licensed prescriber can lawfully write for today, which are waiting on an FDA rule, how telehealth rules work, and the red flags that mean a product is not a prescription at all.
More on the blog
- Peptide before and after: trial results vs marketing photos
- Peptide stacks: what each common component has shown alone
- Peptides for men, ranked by human evidence
- Peptides for muscle growth, ranked by human evidence
- Peptides for weight loss, ranked by human evidence
- What is peptide therapy? What clinics sell, what is legal, and what works
Sources
- [1]FDA prescribing information for Egrifta (tesamorelin for injection), via DailyMedFDA
- [2]FDA prescribing information for Egrifta WR (tesamorelin) for injection, How Supplied section, via DailyMedFDA
- [3]Manufacturer press release, March 25, 2025: FDA approval of Egrifta WR (tesamorelin F8), the once weekly reconstitution formulation replacing Egrifta SV
- [4]Manufacturer prescriber site for Egrifta WR (tesamorelin), including patient support and access program
- [5]Published retail cash price listing for tesamorelin (Egrifta WR) kits, accessed 2026-09-22
- [6]Second published retail cash price listing for tesamorelin (Egrifta WR) kits, accessed 2026-09-22
- [7]FDA: Compounding and the FDA, questions and answers (biological products are not eligible for the 503A or 503B compounding exemptions)FDA
- [8]Medicare.gov: prescription drug coverage (Part D and outpatient drugs)
- [9]FDA: List of approved NDAs for biological products that were deemed to be BLAs on March 23, 2020 (includes tesamorelin, Egrifta and Egrifta SV, application 022505)FDA, 2020